Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Identifieur interne : 000315 ( Main/Corpus ); précédent : 000314; suivant : 000316Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?
Auteurs : Ömer Kutlu ; Ahmet MetinSource :
- Dermatologic therapy [ 1529-8019 ] ; 2020.
Abstract
Recent studies have focused on the comorbid conditions of the COVID-19. According to the current studies, numerous diseases including lung disease, cardiovascular disease and immunosuppression appear to be at higher risk for severe forms of the COVID-19. To date, there are no data in the literature on the comorbid dermatologic diseases and COVID-19. We tried to analyze the previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42 females) who presented to the dermatology outpatient clinics for the last 3 years. The most common dermatologic diseases in patients with COVID-19 who have dermatologic diseases for the last 3 years were superficial fungal infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis (10, 10.8%), psoriasis (6, 6.5%), and eczema (6, 6.5%), respectively. In addition, the number of COVID-19 patients who presented to dermatology in the last 3 months was 17 (11 men, 6 women). The median age of these patients was 58 (minimum 18, maximum 80) years, and the most common dermatologic diseases before diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4, 20%), and viral skin diseases (3, 15%). The possible similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with some dermatologic diseases especially superficial fungal infections and psoriasis may be more vulnerable to the COVID-19.
DOI: 10.1111/dth.13509
PubMed: 32367558
PubMed Central: PMC7261987
Links to Exploration step
pubmed:32367558Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?</title>
<author><name sortKey="Kutlu, Omer" sort="Kutlu, Omer" uniqKey="Kutlu O" first="Ömer" last="Kutlu">Ömer Kutlu</name>
<affiliation><nlm:affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Metin, Ahmet" sort="Metin, Ahmet" uniqKey="Metin A" first="Ahmet" last="Metin">Ahmet Metin</name>
<affiliation><nlm:affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32367558</idno>
<idno type="pmid">32367558</idno>
<idno type="doi">10.1111/dth.13509</idno>
<idno type="pmc">PMC7261987</idno>
<idno type="wicri:Area/Main/Corpus">000315</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000315</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?</title>
<author><name sortKey="Kutlu, Omer" sort="Kutlu, Omer" uniqKey="Kutlu O" first="Ömer" last="Kutlu">Ömer Kutlu</name>
<affiliation><nlm:affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Metin, Ahmet" sort="Metin, Ahmet" uniqKey="Metin A" first="Ahmet" last="Metin">Ahmet Metin</name>
<affiliation><nlm:affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Dermatologic therapy</title>
<idno type="eISSN">1529-8019</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent studies have focused on the comorbid conditions of the COVID-19. According to the current studies, numerous diseases including lung disease, cardiovascular disease and immunosuppression appear to be at higher risk for severe forms of the COVID-19. To date, there are no data in the literature on the comorbid dermatologic diseases and COVID-19. We tried to analyze the previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42 females) who presented to the dermatology outpatient clinics for the last 3 years. The most common dermatologic diseases in patients with COVID-19 who have dermatologic diseases for the last 3 years were superficial fungal infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis (10, 10.8%), psoriasis (6, 6.5%), and eczema (6, 6.5%), respectively. In addition, the number of COVID-19 patients who presented to dermatology in the last 3 months was 17 (11 men, 6 women). The median age of these patients was 58 (minimum 18, maximum 80) years, and the most common dermatologic diseases before diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4, 20%), and viral skin diseases (3, 15%). The possible similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with some dermatologic diseases especially superficial fungal infections and psoriasis may be more vulnerable to the COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32367558</PMID>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-8019</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>May</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Dermatologic therapy</Title>
<ISOAbbreviation>Dermatol Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?</ArticleTitle>
<Pagination><MedlinePgn>e13509</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/dth.13509</ELocationID>
<Abstract><AbstractText>Recent studies have focused on the comorbid conditions of the COVID-19. According to the current studies, numerous diseases including lung disease, cardiovascular disease and immunosuppression appear to be at higher risk for severe forms of the COVID-19. To date, there are no data in the literature on the comorbid dermatologic diseases and COVID-19. We tried to analyze the previous dermatological comorbidity of 93 patients with COVID-19 (51 males, 42 females) who presented to the dermatology outpatient clinics for the last 3 years. The most common dermatologic diseases in patients with COVID-19 who have dermatologic diseases for the last 3 years were superficial fungal infections (24, 25.8%), seborrheic dermatitis (11, 11.8%), actinic keratosis (10, 10.8%), psoriasis (6, 6.5%), and eczema (6, 6.5%), respectively. In addition, the number of COVID-19 patients who presented to dermatology in the last 3 months was 17 (11 men, 6 women). The median age of these patients was 58 (minimum 18, maximum 80) years, and the most common dermatologic diseases before diagnosed COVID-19 were superficial fungal infections (5, 25%), psoriasis (4, 20%), and viral skin diseases (3, 15%). The possible similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with some dermatologic diseases especially superficial fungal infections and psoriasis may be more vulnerable to the COVID-19.</AbstractText>
<CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kutlu</LastName>
<ForeName>Ömer</ForeName>
<Initials>Ö</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-9665-015X</Identifier>
<AffiliationInfo><Affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Metin</LastName>
<ForeName>Ahmet</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-6512-4990</Identifier>
<AffiliationInfo><Affiliation>Uşak University, Department of Dermatology and Venereology, School of Medicine, Uşak, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Dermatol Ther</MedlineTA>
<NlmUniqueID>9700070</NlmUniqueID>
<ISSNLinking>1396-0296</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">dermatology</Keyword>
<Keyword MajorTopicYN="N">immunosuppression</Keyword>
<Keyword MajorTopicYN="N">psoriasis</Keyword>
<Keyword MajorTopicYN="N">superficial fungal infections</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32367558</ArticleId>
<ArticleId IdType="doi">10.1111/dth.13509</ArticleId>
<ArticleId IdType="pmc">PMC7261987</ArticleId>
</ArticleIdList>
<ReferenceList><Title>REFERENCES</Title>
<Reference><Citation>Guo YR, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7(1):1-10.</Citation>
</Reference>
<Reference><Citation>https://covid19.saglik.gov.tr/</Citation>
</Reference>
<Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med. 2020;8(4):e21.</Citation>
</Reference>
<Reference><Citation>Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. China Allergy. 2020. https://doi.org/10.1111/all.14238.</Citation>
</Reference>
<Reference><Citation>Conforti C, Cannavò SP, Jafferany M, et al. Coronavirus disease 2019 (COVID-19): facts and controversies. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13366.</Citation>
</Reference>
<Reference><Citation>Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic?Dermatol Ther. 2020. https://doi.org/10.1111/dth.13383.</Citation>
</Reference>
<Reference><Citation>Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13298.</Citation>
</Reference>
<Reference><Citation>Abdelmaksoud A, Goldust M, Vestita M. Comment on “COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action”. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13360.</Citation>
</Reference>
<Reference><Citation>Kutlu Ö, Doğan Z, Ekşioğlu H, Kekilli M. Relationship between helicobacter pylori infection and pityriasis versicolor: can helicobacter pylori infection be a new etiologic factor for pityriasis versicolor?Turk J Med Sci. 2020. https://doi.org/10.3906/sag-1910-48.</Citation>
</Reference>
<Reference><Citation>Hovav AH. Mucosal and skin langerhans cells-nurture calls. Trends Immunol. 2018;39(10):788-800.</Citation>
</Reference>
<Reference><Citation>Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727-732.</Citation>
</Reference>
<Reference><Citation>Prasad A. Local ımmunity concept in the context of the novel corona viral ınfection: a consideration. Asian J Immunol. 2020;3(2):16-25.</Citation>
</Reference>
<Reference><Citation>Belyakov IM, Hel Z, Kelsall B, et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med. 2001;7(12):1320-1326.</Citation>
</Reference>
<Reference><Citation>Heinen MP, Cambier L, Antoine N, et al. Th1 and Th17 immune responses act complementarily to optimally control superficial dermatophytosis. J Invest Dermatol. 2019;139(3):626-637.</Citation>
</Reference>
<Reference><Citation>Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin d supplementation could reduce risk of ınfluenza and COVID-19 ınfections and deaths. Nutrients. 2020;12(4):988.</Citation>
</Reference>
<Reference><Citation>Cakman I, Kırchener H, Rınk L. Zinc supplementation reconstitutes the production of interferon-α by leukocytes from elderly persons. J Interferon Cytokine Res. 1997;17(8):469-472.</Citation>
</Reference>
<Reference><Citation>Razzaque M. COVID-19 pandemic: can maintaining optimal zinc balance enhance host resistance?Preprints. 2020. https://doi.org/10.20944/preprints202004.0006.v1.</Citation>
</Reference>
<Reference><Citation>Wikramanayake TC, Borda LJ, Miteva M, Paus R. Seborrheic dermatitis-looking beyond malassezia. Exp Dermatol. 2019;28(9):991-1001.</Citation>
</Reference>
<Reference><Citation>Aktaş Karabay E, Aksu ÇA. Serum zinc levels in seborrheic dermatitis: a case-control study. Turk J Med Sci. 2019;49(5):1503-1508.</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CardioCovidV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32367558 |texte= Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32367558" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CardioCovidV1
This area was generated with Dilib version V0.6.35. |